-
Jefferies & Company Raises Incyte (INCY) Target Price To $19
Tuesday, March 23, 2010 - 9:28am | 144Read More...Jefferies & Company analysts Thomas Wei, Thomas Nguyen and Shaunak Deepak maintained their Buy rating for shares of Incyte Corporation (Nasdaq: INCY) and raised the price target from $13 to $19 per share. The analysts spoke to three of Incyte Corporation's investigators about the prospects of...
-
Jefferies & Company Raises ViroPharma (VPHM) Price Target To $18
Monday, March 22, 2010 - 12:51pm | 177Read More...Jefferies & Company analysts Thomas Wei, Shaunak Deepak and Thomas Nguyen rated shares of ViroPharma Incorporated (Nasdaq: VPHM) a Buy and raised the price target from $16 to $18. The analysts said that there were a number of ways ViroPharma Incorporated would benefit from health care reform....
-
Jefferies & Company Maintains Auxilium Pharmaceuticals (AUXL) Buy Rating
Monday, March 22, 2010 - 12:10pm | 119Read More...Jefferies & Company analysts Thomas Wei, Shaunak Deepak and Thomas Nguyen rated shares of Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) a Buy, with a price target of $44. The analysts said that like many biotech companies, Auxilium Pharmaceuticals, Inc is set to benefit greatly from health care...
